![]() ![]() Use of CINVANTI with strong CYP3A4 inducers (e.g., rifampin) may result in a reduction in aprepitant plasma concentrations and decreased efficacy of CINVANTI. ![]() Use of CINVANTI with strong or moderate CYP3A4 inhibitors (e.g., ketoconazole, diltiazem) may increase plasma concentrations of aprepitant and result in an increased risk of adverse reactions related to CINVANTI.Use of pimozide with CINVANTI is contraindicated due to the risk of significantly increased plasma concentrations of pimozide, potentially resulting in prolongation of the QT interval, a known adverse reaction of pimozide.Use of CINVANTI with other drugs that are CYP3A4 substrates may result in increased plasma concentration of the concomitant drug.Warnings and PrecautionsĬlinically Significant CYP3A4 Drug InteractionsĪprepitant is a substrate, weak-to-moderate (dose-dependent) inhibitor, and an inducer of CYP3A4. IMPORTANT SAFETY INFORMATION ContraindicationsĬINVANTI is contraindicated in patients with hypersensitivity to any of the components of CINVANTI.Ĭoncurrent use of pimozide with CINVANTI is contraindicated. Limitations of Use: CINVANTI has not been studied for treatment of established nausea and vomiting. Determination will be made by the manufacturer of CINVANTI.ĬINVANTI is a substance P/neurokinin-1 (NK 1) receptor antagonist, indicated in adults, in combination with other antiemetic agents, for the prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin as a single-dose regimen delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC) as a single-dose regimen and nausea and vomiting associated with initial and repeat courses of MEC as a 3-day regimen.A qualifying claim denial can be reviewed for the Heron Commitment Program when, for a patient covered under commercial insurance, the following criteria have been met, and documentation confirms: (a) the verification of benefits, conducted by the provider and/or Heron Connect, meets all of the payer criteria and/or policy requirements, (b) the submitted claim for the Heron product is denied, and (c) the claim has been denied again by the commercial payer after the first level of appeals process has been followed.Use of CINVANTI and/or SUSTOL may be discontinued at any time, without penalty. The Heron Commitment Program and the other product support programs offered by Heron Therapeutics do not impose any purchase obligation at any time or in any manner.Product supply for the program depends on availability. All patient information remains confidential. Heron Therapeutics, Inc., reserves the right, at its sole discretion, to discontinue the Heron Connect Patient Assistance Program or change the qualifications at any time. ![]() Eligibility is for 12 months, after which patient will need to reapply for continued assistance. For cash-paying patients, the program will cover $150 per prescription up to $1,800 per calendar year. When applicable, deductible assistance up to $200 per treatment will be covered. Patients pay $0 per copay per dose per 12-month calendar period. Offer not valid as follows: (a) patients covered under Medicare, Medicaid, or any federal or state program (b) where plan covers treatment for the patient for the entire cost of the prescription drug. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |